NEW YORK (GenomeWeb) – Illumina announced today that it has applied the CE mark to its VeriSeq noninvasive prenatal testing analysis software, expanding its use to clinical laboratories.
The VeriSeq software is designed to analyze sequencing information from cell-free DNA to help detect fetal trisomies for chromosomes 21, 18, and 13, as well as sex chromosomal aneuploidy. It can be run in-lab and does not require data to be uploaded to off-site servers.
"This registration underscores our commitment to providing robust, high-quality solutions to meet the needs of our laboratory partners in the EU while meeting safety and quality requirements," Jeff Hawkins, VP and GM of reproductive and genetic health at Illumina, said in a statement.